bioAffinity Technologies, Inc. (BIAF)
2.15
+0.22
(+11.40%)
USD |
NASDAQ |
Nov 18, 16:00
2.08
-0.07
(-3.26%)
After-Hours: 20:00
bioAffinity Technologies Gross Profit Margin (Quarterly) : -10.34% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -10.34% |
| June 30, 2026 | 23.91% |
| March 31, 2026 | 22.82% |
| December 31, 2025 | 35.72% |
| September 30, 2025 | 27.00% |
| June 30, 2025 | 11.00% |
| March 31, 2025 | 17.86% |
| December 31, 2024 | 22.28% |
| September 30, 2024 | 32.29% |
| Date | Value |
|---|---|
| June 30, 2024 | 34.99% |
| March 31, 2024 | 28.40% |
| December 31, 2023 | 18.06% |
| September 30, 2023 | 55.68% |
| June 30, 2023 | -15.23% |
| March 31, 2023 | -2.32K% |
| December 31, 2022 | -226.1% |
| September 30, 2022 | 16.67% |
| June 30, 2022 | 7.69% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 61.57% |
| Perspective Therapeutics, Inc. | -5.86K% |
| MiMedx Group, Inc. | 79.33% |
| Veracyte, Inc. | 70.30% |
| T2 Biosystems, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -280.0% |
| Return on Assets | -168.9% |
| Return on Invested Capital | -228.8% |
| Profit Margin (Quarterly) | -493.0% |
| Operating Margin (Quarterly) | -328.0% |
| Return on Net Operating Assets | -349.6% |